Insmed reported strong Q2 2024 financial results with product revenues increasing 17% to $90.3 million, driven by ARIKAYCE sales growth across all regions. US sales rose 10.6% to $63.8 million, while Japan and Europe saw growth of 35.4% and 36.9% respectively. The company ended the quarter with $1.25 billion in cash and cash equivalents.The company announced positive topline results from its Phase 3 ASPEN trial of brensocatib, meeting its primary endpoint with both dosage strengths demonstrating statistically significant reductions in pulmonary exacerbations versus placebo. Based on these results, Insmed plans to file an NDA with the FDA in Q4 2024, followed by European and Japanese regulatory submissions.R&D expenses decreased to $146.7 million from $197.0 million year-over-year, while SG&A expenses increased 26.2% to $106.6 million due to higher compensation costs and commercial readiness activities. The company strengthened its financial position through a successful equity offering in May 2024, raising net proceeds of $713.2 million.

Insmed reported strong Q2 2024 financial results with product revenues increasing 17% to $90.3 million, driven by ARIKAYCE sales growth across all regions. US sales rose 10.6% to $63.8 million, while Japan and Europe saw growth of 35.4% and 36.9% respectively. The company ended the quarter with $1.25 billion in cash and cash equivalents.The company announced positive topline results from its Phase 3 ASPEN trial of brensocatib, meeting its primary endpoint with both dosage strengths demonstrating statistically significant reductions in pulmonary exacerbations versus placebo. Based on these results, Insmed plans to file an NDA with the FDA in Q4 2024, followed by European and Japanese regulatory submissions.R&D expenses decreased to $146.7 million from $197.0 million year-over-year, while SG&A expenses increased 26.2% to $106.6 million due to higher compensation costs and commercial readiness activities. The company strengthened its financial position through a successful equity offering in May 2024, raising net proceeds of $713.2 million.